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Abstract
Owing to its unique host cell-dependent development cycle, Chlamydia pneumoniae occupies an intracellular niche that enables the bac-
terium to survive and to multiply, secluded from both the extracellular and the cytoplasmic environments. Within its separate chlamy-
dial inclusion, it is able to genetically switch between a replicative and a persisting non-replicative state, linking the pathogen to acute as
well as chronic diseases. Although its role in acute respiratory infection has been established, a potential link between chronic vascular
infection with C. pneumoniae and the development of atherosclerosis remains enigmatic, in particular because chronic chlamydial infec-
tion cannot be eradicated by antibiotics. C. pneumoniae has developed numerous mechanisms to establish an adequate growth milieu
involving the type III secretion-mediated release of chlamydial effector proteins that interact with cellular structures and reprogram host
cell regulatory pathways. This brief overview of these pathomechanisms focuses on chronic vascular infection.
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Introduction
Chlamydia pneumoniae is an obligate intracellular bacterium
causing respiratory infections such as acute pneumonia,
bronchitis, sinusitis and pharyngitis. Up to 10% of cases of
community-acquired pneumonia are apparently caused by
C. pneumoniae. Re-infections are common, with studies indi-
cating seroprevalence in c. 80% of adults. C. pneumoniae has
been detected in atherosclerotic lesions, but not in unda-
maged vasculature, potentially linking the bacterium to ather-
osclerotic processes. C. pneumoniae is able to enter a non-
replicative persistent state within host cells, forming mor-
phologically aberrant inclusions. Persistent C. pneumoniae is
refractory to antibiotic treatment and is associated with
chronic infection, as shown in infected vasculature. Living
separated from the host cell cytoplasm within its chlamydial
inclusion (a non-lysosomal vacuole), C. pneumoniae has cre-
ated an intracellular niche from where it promotes host cell
survival or death, modulates regulatory host cell signalling
pathways, and bypasses the host cell’s defence mechanisms.
Chlamydial Persistence and Antibiotic
Treatment
One result of chlamydial evolution is its intracellular niche,
permitting a unique life cycle in which the bacterium expresses
different phenotypes. Elementary bodies (EBs), the metaboli-
cally inactive but infective forms, are able to attach to the tar-
get cell and promote active ingestion by the target cell. Within
the cell, EBs transform into the metabolically active but non-
infective form of the reticulate bodies; after 48–72 h, these
reorganize into EBs, which are released after host cell lysis.
Besides this replicative life cycle, which represents acute chla-
mydial infection, chlamydiae may enter a persistent state
within the host cell that is characterized by metabolic and
structural changes. Persistent C. pneumoniae organisms have an
atypical ultrastructural morphology with inclusions that show
only a few enlarged bodies [1] or aberrant structures [2]
(Fig. 1) and an altered gene expression proﬁle, e.g. for outer
membrane proteins OmpA and OmpB or inclusion membrane
proteins [1,3]. Byrne et al. [4] demonstrated that persistent
C. pneumoniae organisms show enhanced expression of the
genes required for DNA replication, but not of the genes
essential for bacterial cell division. However, the persistent
state is lacking an exact deﬁnition in genetic terms. As the chla-
mydial type III secretion (T3S) apparatus (see below) appears
to remain fully functional during chronic infection, chlamydiae
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may continuously release effector proteins into the host cell
cytoplasm, ensuring a C. pneumoniae-adjusted environment.
This is of particular interest, as C. pneumoniae was reproduci-
bly recovered from atherosclerotic lesions [5]. In many stu-
dies, the pathogen has been related to the development of
atherosclerosis [6]. Chronic persistent infection of vascular
cells indeed leads to proproliferative and proinﬂammatory
phenotypes within the infected vasculature in vitro and in vivo.
However, attempts to eradicate C. pneumoniae in patients with
cardiovascular diseases have all failed [7–9]. This can easily be
explained by the fact that the persistent state is completely
refractory to antibiotic treatment [10]. In fact, ﬁrst-choice
antichlamydial drugs may even induce chlamydial persistence
under certain conditions [11]. In the absence of a functional
treatment strategy, the hypothesis of a chlamydial contribution
to atherogenetic processes can thus neither be proved nor
disproved by eradication studies, and a better understanding
of chlamydial pathobiology is needed before implementing clin-
ical studies.
The Type III Secretion Apparatus
The C. pneumoniae genome contains all the genes necessary
for the T3S machinery, a molecular injection apparatus pro-
truding from the outer membrane that appears to be
expressed and functional in acute, as well as in chronic, infec-
tion [12,13] and thus may represent a prominent virulence
factor. A functional injectisome enables C. pneumoniae to
translocate toxic effector proteins into the host cell that
then adversely modulate the cellular response. However, lit-
tle information is available concerning individual
C. pneumoniae proteins and their interactions. Although the
studies on chlamydial T3S systems have revealed many simi-
larities, some species-speciﬁc differences exist. Most notably,
C. pneumoniae lacks the phosphorylation site of the T3S-asso-
ciated actin-recruiting protein, tyrosine-phosphorylated pro-
tein, phosphorylation of which is thought to be essential for
Chlamydia trachomatis endocytosis [14]. This suggests that
there are T3S-dependent differences between chlamydial
species in the signal transduction pathways needed for entry.
The spectrum of putatively T3S-secreted proteins apparently
differs between C. trachomatis and C. pneumoniae [15], also
indicating differences in their pathobiology. Stone recently
reported an interaction of four putative T3S structural com-
ponents and a chaperone with CdsN, the predicted T3S
ATPase of C. pneumoniae, which has not been described in
other bacterial T3S machineries and which may have implica-
tions for ATPase function at the C. pneumoniae inner mem-
brane [16]. For the obligate intracellular chlamydiae, a major
role of a functional T3S may also, or even predominantly, be
in securing growth and development of the pathogen by
modifying apoptosis signals or some other transcriptional
regulation important for chlamydial survival. The chlamydial
injectisome consists of approximately 25 proteins, which can
be predicted from sequence homologies. Effector proteins, in
contrast, share much less homology and cannot be readily
predicted. In a directed screen in a surrogate Shigella secre-
tion system expressing putative chlamydial T3S effectors,
Subtil et al. were able to deﬁne 24 effector proteins [17].
Not all may ultimately prove to be T3S-dependently secreted
in vivo, but as a tractable genetic system for chlamydiae is still
absent, this information provides a promising set of potential
modiﬁers of host cell signalling, which, together with their
interacting host proteins, constitute possible targets for
interrupting chlamydial reprogramming of the host cell. Their
examination will result in a better understanding of chlamy-
dial pathogenesis and may result in new therapeutic strate-
gies. Also, the members of the inclusion-membrane localized
protein family, chlamydial proteins that are anchored to the
inclusion membrane and share the structural motif of a large
bi-lobed hydrophobic domain, are candidate effectors for
type III secretion [18] and need further examination regard-
ing potential disruption of host cell transcriptional signalling.
The T3S apparatus is well expressed in interferon-c-mediated
(a) (b)
FIG. 1. Immunoﬂuorescence microscopy of a chronically Chlamydia
pneumoniae-infected peripheral human blood monocyte (a) and an
acutely infected respiratory epithelial HEp2 cell (b) 72 h post-infection
(ﬂuorescein isothiocyanate-labeled anti-Chlamydia lipopolysaccharide
antibody; Dako, Hamburg, Germany). (a) Persistent chlamydial infec-
tion can be detected over prolonged periods in mononuclear cells
ex vivo. Peripheral blood mononuclear cells can differentiate into
monocyte-derived macrophages or into dendritic cells. The numerous
small and morphologically aberrant inclusions seen here are indicative
of persistent infection (arrow). Their appearance does not alter sub-
stantially over the lifetime of the cell, and they do not release new
infective elementary bodies. (b) Typical productive infection in epithe-
lial cells (HEp-2 cells) characterized by large inclusions ﬁlled with
abundant elementary bodies ready for release by host cell lysis. This is
the in vitro equivalent of acute infection leading to cell death.
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models of chlamydial persistence [19]. Biomathematical mod-
elling and T3S inhibition by small molecules have recently
been used to gain new insights into T3S function in the
developmental cycle and into chlamydial persistence [20].
This important area of research has recently been exten-
sively reviewed [12].
C. Pneumoniae Inhibits Host Cell Apoptosis
Cell death by apoptosis is an active and important defence
mechanism against invading pathogens. Whereas in acute
chlamydial infection host cell lysis is obviously crucial for
infective EBs to be released from the host cell, in chronic
infection C. pneumoniae has been shown to successfully
escape from this programmed cell death by inhibiting apopto-
tic signalling cascades within various host cell populations
[21], e.g. monocytes [22], epithelial cells [23] or microglial
cells [24]. Proapoptotic BH3-only proteins (Bim and others),
which stimulate apoptotic events, can be efﬁciently degraded
by C. pneumoniae. As experiments with C. trachomatis show,
this effect seems to be mediated by targeting proteins for
proteosomal destruction [25]. Furthermore, the release of
the important apoptotic trigger protein cytochrome c can be
inhibited by chlamydiae, and caspase-3 activity is reduced in
C. pneumoniae-infected HeLa cells. Viable bacteria are
required for these effects [26]. In early pulmonary infection,
C. pneumoniae is ingested by neutrophil granulocytes. Within
these cells, the bacterium is able to survive and multiply by
delaying the programmed host cell apoptosis via inhibition of
procaspase-3 and enhanced antiapoptotic interleukin (IL)-8
expression [27]. Transmission of the bacterium to mononuc-
lear cells and systemic dissemination can result. Many studies
assume a central role of the transcription factor nuclear fac-
tor kappa-B (NF-jB) in antiapoptotic effects. However, its
impact still remains controversial [26,28,29]. By gaining con-
trol over the host cell apoptotic regulation, chlamydiae can
thus create the appropriate environment for replication or
persistence.
Inﬂammatory Response and Development
of an Atherogenetic Phenotype in Infected
Cells
C. pneumoniae can invade a large variety of cells (e.g. vascular
endothelial cells and smooth muscle cells, alveolar epithelial
cells, ﬁbroblasts, mononuclear cells, T-cells and dendritic
cells, but also neuronal glia cells), which will almost invariably
lead to enhanced expression of numerous inﬂammatory che-
mokines and cytokines [6,30–41], which are usually regulated
via small GTPase activation and subsequent activation of NF-
jB heterodimers (Table 1). Under in vitro conditions, vascu-
lar endothelial cells and smooth muscle cells are highly sus-
ceptible to C. pneumoniae infection [42,43], and develop a
proatherosclerotic and proproliferative phenotype. This
in vitro constellation might lead to complex vascular altera-
tions in vivo, e.g. endothelial dysfunction, destruction of
endothelial integrity and the basal membrane by proliferating
smooth muscle cells, and maintenance of atherosclerotic pla-
ques and subsequent plaque rupture. This highlights the need
for further genomic analyses regarding the hypothesis of a
role of C. pneumoniae in nearly all stages of atherogenesis.
Induction of Vascular Cell Proliferation
Upon C. Pneumoniae Infection
To date, three key elements of atherosclerotic development
have been identiﬁed: inﬂammation and proliferation of vascu-
lar wall cells, and endothelial dysfunction. The potential role
of C. pneumoniae as a trigger of inﬂammatory processes
within the vasculature was described above. In addition,
C. pneumoniae seems to have relevant promitogenic proper-
ties. A connection between vascular cell proliferation, a hall-
mark of atherogenesis, and chlamydial infection would
certainly highlight the possible relevance of bacterial infection
in atherosclerotic development.
TABLE 1. Enhanced expression of effector proteins and mediators resulting from Chlamydia pneumoniae infection
Cell population Enhanced expression of effectors and mediators resulting from C. pneumoniae infection References
Vascular endothelial cells (human) ICAM-1, VCAM-1, IL-6, IL-8, PAI-1, TF [30,31]
Vascular smooth muscle cells (human) IL-6, RANTES (CCL5), MCP-1, FGF-2, Egr-1 [32–34]
Peripheral blood mononuclear cells (human) IL-1b, IL-6, IL-8, IL-12, MCP-1, TNF-a, MMP-1, MMP-2, MMP-7, MMP-9, PGE2 [6,35–38]
Mast cells (human) IL-8, MCP-1, TNF-a [39]
Lung epithelial cells (human) IL-8, IFN-c, TNF-a [40]
Glia cells (murine) IL-10, IL-12, TNF-a, MMP-9 [41]
FGF-2, ﬁbroblast growth factor-2; ICAM-1, intercellular adhesion molecule-1; IFN-c, interferon-c; IL, interleukin; MCP-1, monocyte chemotactic protein-1; MMP, matrix
metalloproteinase; PAI-1, plasminogen activator inhibitor-1; PGE2, prostaglandin E2; TF, tissue factor; TNF-a, tumour necrosis factor-a; VCAM-1, vascular cell adhesion
molecule-1.
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There are reports on various signalling cascades and pro-
cesses describing a proliferation-promoting potency of
C. pneumoniae. The angiogenic transcription factor Egr-1 was
depicted as one relevant mediator causing post-infectious
coronary artery smooth muscle cell proliferation [34].
In infected endothelial cells, IL-8, which has angiogenic prop-
erties, was upregulated in an NF-jB-dependent pathway [44]
that was mediated via the nucleotide-binding oligomerization
domain-1 (Nod-1) protein, an intracellular pattern recogni-
tion receptor. Chlamydial heat shock protein 60 (HSP60) is
able to induce vascular smooth muscle cell proliferation in a
p44/42–mitogen-activated protein kinase-dependent manner,
whereas viable chlamydiae were not necessary for this prolif-
eration [45]. Even human HSP60, which co-localizes with
chlamydial HSP60 in atherosclerotic lesions [37,46], might
contribute to C. pneumoniae-dependent vascular cell prolif-
eration [47]. Coombes and Mahony [32], who examined the
complex cell–cell communication within the vascular wall,
reported that the supernatant of C. pneumoniae-infected
endothelial cells contained one or more soluble factors caus-
ing vascular smooth muscle cell proliferation in a time- and
dose-dependent manner. Viable chlamydiae were not
required for this effect. Possible endothelium-derived factors
might be platelet-derived growth factor, ﬁbroblast growth
factor, IP-10 or monocyte chemotactic protein-1. Indeed pla-
telet-derived growth factor was later found to be enhanced
in C. pneumoniae-infected endothelium [48].
Target Cell Activation by C. Pneumoniae
C. pneumoniae-induced host cell activation and reprogram-
ming is a complex mechanism, and involves several receptor
systems and signalling pathways of the host cell. Mitogen-
activated protein kinase p38, p44/42 and c-Jun-kinase are
phosphorylated upon C. pneumoniae infection and, by stimu-
lation of IL-8 or intercellular adhesion molecule-1, cause the
development of a proinﬂammatory phenotype in vascular
cells [49]. Furthermore, the transcription factor NF-jB,
which mediates many inﬂammatory processes within cells,
can be activated by C. pneumoniae, and translocates into the
nucleus [50]. Toll-like receptor (TLR) 2 and TLR 4, surface
receptors that mediate recognition patterns, have been
reported to be essential mediators of C. pneumoniae-related
host cell activation and defence [51]. Additionally, TLR 2
was demonstrated to be crucial for NF-jB translocation in
dendritic cells [52]. Members of the recently described
nucleotide-binding oligomerization domain protein family,
which are involved in intracellular pattern recognition, are
implicated in C. pneumoniae-induced target cell activation
with regard to transcription factors and cytokines such as
IL-8 [44].
Conclusion and Perspective
C. pneumoniae pathogenesis is a complex process that
depends on the cell population invaded, the initiation of the
replicative or non-replicative genetic state of the pathogen,
and the efﬁciency of the release of effector molecules into
the host cell. Unfortunately, a genetic system for directed
mutagenesis of intracellular chlamydiae is still lacking, which
leaves the pathogen somewhat intractable to standard
approaches of bacterial genetics. The key to understanding
the pathobiology of chronic chlamydial infection is clearly in
the genetics of the treatment-refractory persistent state, in
which C. pneumoniae has proved to be untreatable with com-
mon antibiotics, and in which chlamydial inclusions show
both aberrant structural behaviour and protein expression.
Signal transduction studies, and closer examination of the
chlamydial T3S apparatus in acute and chronic infection, have
revealed that C. pneumoniae can efﬁciently modify vascular sig-
nalling to produce the inﬂammatory and proproliferative phe-
notypes that are characteristic of atherogenesis. The potential
reprogramming of infected vascular host cells into proathero-
genic foci has actually made the hypothesis of a bacterial con-
tribution to atherosclerosis more attractive than ever,
although a proof of principle by elimination of vascular chlamy-
diae and regression of atherosclerotic lesions remains out of
reach. The host cell responds to a chronic noxious stimulus in
a way that is also seen in atherosclerosis. Chlamydiae may con-
stitute one among many such stimuli promoting atherogenesis,
the degree of its involvement remaining undetermined. Any
approach to understanding chronic chlamydial disease, and to
eradicating chlamydiae from infected tissues, will have to rely
on a ‘pathogenomics’ approach: the functional analysis of the
interaction of bacterial gene products with the regulatory sig-
nalling cascades of the host cell at a genome-wide level in both
pathogen and host.
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